5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Increases O
in O
Blood O
Pressure O
: O
MYRBETRIQ O
( O
r O
) O
can O
increase O
blood O
pressure O
. O

Periodic O
blood O
pressure O
determinations O
are O
recommended O
, O
especially O
in O
hypertensive O
patients O
. O

MYRBETRIQ O
( O
r O
) O
is O
not O
recommended O
for O
use O
in O
severe O
uncontrolled O
hypertensive O
patients O
( O
5.1 O
) O
. O

* O
Urinary O
Retention O
in O
Patients O
With O
Bladder O
Outlet O
Obstruction O
and O
in O
Patients O
Taking O
Antimuscarinic O
Drugs O
for O
Overactive O
Bladder O
: O
Administer O
with O
caution O
in O
these O
patients O
because O
of O
risk O
of O
urinary O
retention O
( O
5.2 O
) O
. O

* O
Angioedema O
: O
Angioedema O
of O
the O
face O
, O
lips O
, O
tongue O
and/or O
larynx O
has O
been O
reported O
with O
MYRBETRIQ O
( O
r O
) O
( O
5.3 O
, O
6.2 O
) O
. O

* O
Patients O
Taking O
Drugs O
Metabolized O
by O
CYP2D6 O
: O
MYRBETRIQ O
( O
r O
) O
is O
a O
moderate O
inhibitor O
of O
CYP2D6 O
. O

Appropriate O
monitoring O
is O
recommended O
and O
dose O
adjustment O
may O
be O
necessary O
for O
narrow O
therapeutic O
index O
CYP2D6 O
substrates O
( O
5.4 O
, O
7.1 O
, O
12.3 O
) O
. O

5.1 O
Increases O
in O
Blood O
Pressure O
MYRBETRIQ O
( O
r O
) O
can O
increase B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

Periodic O
blood O
pressure O
determinations O
are O
recommended O
, O
especially O
in O
hypertensive B-Not_AE_Candidate
patients O
. O

MYRBETRIQ O
( O
r O
) O
is O
not O
recommended O
for O
use O
in O
patients O
with O
severe O
uncontrolled B-Not_AE_Candidate
hypertension I-Not_AE_Candidate
( O
defined O
as O
systolic B-Not_AE_Candidate
blood I-Not_AE_Candidate
pressure I-Not_AE_Candidate
greater I-Not_AE_Candidate
than I-Not_AE_Candidate
or I-Not_AE_Candidate
equal I-Not_AE_Candidate
to I-Not_AE_Candidate
1 I-Not_AE_Candidate
8 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mm I-Not_AE_Candidate
Hg I-Not_AE_Candidate
and/or O
diastolic B-Not_AE_Candidate
blood I-Not_AE_Candidate
pressure I-Not_AE_Candidate
greater I-Not_AE_Candidate
than I-Not_AE_Candidate
or I-Not_AE_Candidate
equal I-Not_AE_Candidate
to I-Not_AE_Candidate
1 I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mm I-Not_AE_Candidate
Hg I-Not_AE_Candidate
) O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

In O
two O
, O
randomized O
, O
placebo-controlled O
, O
healthy O
volunteer O
studies O
, O
MYRBETRIQ O
( O
r O
) O
was O
associated O
with O
dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

In O
these O
studies O
, O
at O
the O
maximum O
recommended O
dose O
of O
50 O
mg O
, O
the O
mean O
maximum O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
/diastolic O
blood O
pressure O
was O
approximately O
3.5/1.5 O
mm O
Hg O
greater O
than O
placebo O
. O

In O
contrast O
, O
in O
OAB B-Not_AE_Candidate
patients O
in O
clinical O
trials O
, O
the O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
and O
diastolic O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
at O
the O
maximum O
recommended O
dose O
of O
50 O
mg O
was O
approximately O
0.5 O
- O
1 O
mm O
Hg O
greater O
than O
placebo O
. O

Worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
was O
reported O
infrequently O
in O
MYRBETRIQ O
( O
r O
) O
patients O
. O

5.2 O
Urinary O
Retention O
in O
Patients O
with O
Bladder O
Outlet O
Obstruction O
and O
in O
Patients O
Taking O
Antimuscarinic O
Medications O
for O
OAB O
Urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
in O
patients O
with O
bladder B-Not_AE_Candidate
outlet I-Not_AE_Candidate
obstruction I-Not_AE_Candidate
( O
BOO O
) O
and O
in O
patients O
taking O
antimuscarinic O
medications O
for O
the O
treatment O
of O
OAB B-Not_AE_Candidate
has O
been O
reported O
in O
postmarketing O
experience O
in O
patients O
taking O
mirabegron O
. O

A O
controlled O
clinical O
safety O
study O
in O
patients O
with O
BOO B-Not_AE_Candidate
did O
not O
demonstrate O
increased B-NonOSE_AE
urinary I-NonOSE_AE
retention I-NonOSE_AE
in O
MYRBETRIQ O
( O
r O
) O
patients O
; O
however O
, O
MYRBETRIQ O
( O
r O
) O
should O
be O
administered O
with O
caution O
to O
patients O
with O
clinically O
significant O
BOO B-Not_AE_Candidate
. O

MYRBETRIQ O
( O
r O
) O
should O
also O
be O
administered O
with O
caution O
to O
patients O
taking O
antimuscarinic O
medications O
for O
the O
treatment O
of O
OAB B-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

5.3 O
Angioedema O
Angioedema B-OSE_Labeled_AE
of O
the O
face O
, O
lips O
, O
tongue O
, O
and/or O
larynx O
has O
been O
reported O
with O
MYRBETRIQ O
( O
r O
) O
. O

In O
some O
cases O
angioedema B-OSE_Labeled_AE
occurred O
after O
the O
first O
dose O
. O

Cases O
of O
angioedema B-OSE_Labeled_AE
have O
been O
reported O
to O
occur O
hours O
after O
the O
first O
dose O
or O
after O
multiple O
doses O
. O

Angioedema B-NonOSE_AE
associated O
with O
upper B-NonOSE_AE
airway I-NonOSE_AE
swelling I-NonOSE_AE
may O
be O
life O
threatening O
. O

If O
involvement O
of O
the O
tongue O
, O
hypopharynx O
, O
or O
larynx O
occurs O
, O
promptly O
discontinue O
MYRBETRIQ O
( O
r O
) O
and O
initiate O
appropriate O
therapy O
and/or O
measures O
necessary O
to O
ensure O
a O
patent O
airway O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.4 O
Patients O
Taking O
Drugs O
Metabolized O
by O
CYP2D6 O
Since O
mirabegron O
is O
a O
moderate O
CYP2D6 O
inhibitor O
, O
the O
systemic O
exposure O
to O
CYP2D6 O
substrates O
such O
as O
metoprolol O
and O
desipramine O
is O
increased O
when O
co-administered O
with O
mirabegron O
. O

Therefore O
, O
appropriate O
monitoring O
and O
dose O
adjustment O
may O
be O
necessary O
, O
especially O
with O
narrow O
therapeutic O
index O
drugs O
metabolized O
by O
CYP2D6 O
, O
such O
as O
thioridazine O
, O
flecainide O
, O
and O
propafenone O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

